← Back to catalogue

Safire™ TX Ablation Catheter, Safire™ TX, Catheter Extension Cable, Therapy™ Du…

FDA PMA

Class III (US FDA PMA)

PMA P040042

by Irvine Biomedical, Inc.(Ibi)

Identity

Trade Name
THERAPY DUAL 8 CARDIAC ABLATION SYSTEM,THERAM 8MM THERMISTER ABLATION CATHETER SAFIRE TX ABLATION CATHETER FDA PMA
Generic Name
catheter, percutaneous, cardiac ablation, for treatment of atrial flutter FDA PMA

Identifiers

PMA Number
P040042 FDA PMA
FDA Product Code
OAD FDA PMA

Classification

Device Class
Class III FDA PMA
Advisory Committee
Cardiovascular FDA PMA
FDA Decision
APPR Approved FDA PMA

This device is a catheter, percutaneous, cardiac ablation, for treatment of atrial flutter, designed to deliver controlled thermal energy to the heart tissue. It is used to create precise lesions that interrupt abnormal electrical pathways responsible for atrial flutter, a type of irregular heartbeat. The system includes an ablation catheter and extension cables to facilitate targeted treatment during cardiac procedures.

The Therapy Dual-8 Cardiac Ablation System is supplied as a sterile, single-use device intended for use in electrophysiology laboratories under fluoroscopic guidance. It is classified as a Class III medical device under FDA regulations and requires professional medical supervision. The system includes various cable configurations (e.g., Cables 16-17-1) to accommodate different procedural needs, and its use is authorized under PMA number P040042 for the specified indication.

This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them.

Authorization Coverage (1 country)

Regulatory Authorizations

United States Active

FDA_PMA

Is this your device? Claim it to add documentation and request validation.

Manufacturer

FDA Applicant
Irvine Biomedical,Inc.(Ibi)

Sources (1)

  • FDA PMA P040042 24 fields · synced Oct 6, 2026